IL33 and pyoderma gangrenosum: Furthermore, the simultaneous blockade of IL-1, IL-33, and IL-36 using an anti-IL-1RAP antibody may also be of interest beyond already recognized indications such as DIRA, GPP, and DITRA, for other inflammatory skin diseases including psoriasis, AD, hidradenitis suppurativa, and pyoderma gangrenosum and pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome.